A study comparing the new drug PG413 produced by Celon Pharma SA with the drug Eliquis available on the market in healthy volunteers.

and prevention of recurrent DVT and PE in adults., Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF), such as prior stroke or transient ischaemic attack (TIA); age≥ 75 years; hypertension; diabetes mellitus; symptomatic heart failure (NYHA Class ≥ II). Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), with one or more risk factors

No related papers found yet.

None listed

Poland